New hiv drugs 2019
Here are some new HIV drugs approved in 2019:
- Cabotegravir (Cabenuva): A long-acting injectable HIV treatment approved by the FDA in November 2019. It is a two-drug regimen that combines cabotegravir, an integrase inhibitor, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor. Cabenuva is administered every 4-8 weeks, making it a convenient and flexible treatment option.
- Bictegravir (Biktarvy): A single-tablet regimen approved by the FDA in March 2019. Biktarvy is a combination of bictegravir, an integrase inhibitor, with emtricitabine and tenofovir alafenamide, both nucleoside reverse transcriptase inhibitors. It is a once-daily treatment option for adults with HIV-1 infection.
- Doravirine (Pifeltro): A non-nucleoside reverse transcriptase inhibitor approved by the FDA in May 2019. Pifeltro is a once-daily tablet that can be used as a standalone treatment or in combination with other antiretroviral medications.
- Lamivudine (Epivir): A nucleoside reverse transcriptase inhibitor approved by the FDA in June 2019. Epivir is a generic version of lamivudine, which is already widely used to treat HIV and hepatitis B.
- Tenofovir alafenamide (Vemlidy): A nucleotide reverse transcriptase inhibitor approved by the FDA in July 2019. Vemlidy is a generic version of tenofovir alafenamide, which is already widely used to treat HIV and hepatitis B.
These new HIV drugs offer improved treatment options for people living with HIV, including:
- Increased efficacy and potency
- Simplified treatment regimens
- Fewer side effects
- Improved tolerability
- Increased flexibility in dosing and administration
It's essential to note that HIV treatment is highly individualized, and the best treatment option for a person living with HIV will depend on their specific needs, medical history, and other factors. It's crucial to consult with a healthcare provider to determine the most appropriate treatment regimen.